As the results of the EMPAREG OUTCOME, the CANVAS and the DECLARE-TIMI 58 Studies confirmed the favorable profile of this class of anti-diabetic agents among patients with T2DM and HF, the notion that SGLT-2 inhibitors could be beneficial in patients with HF, even without T2D, led to the assumption that SGLT-2 inhibitors could be tested among patients with HF but without T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.